Payment overview · 2025
General Payments
$567.05
22 reported records · 13 companies
Healthcare provider profile · identity verified
Sikander Kajani, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NORTHRIDGE, CA · NPI 1851380992
Verified facts
What the public records show
CMS Open Payments records show Sikander Kajani, M.D. received $567.05 in general payments during 2025 across 22 reported records.
ACADIA Pharmaceuticals Inc accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $81.39 | 14.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.97 | 13.2% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $66.44 | 11.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.01 | 11.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $59.54 | 10.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.03 | 10.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.44 | 5.7% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$30.18 | 5.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.72 | 4.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.63 | 3.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.82 | 3.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.67 | 3.3% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $16.21 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $567.05 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $103.49 | 4 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $81.39 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $66.44 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $59.54 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.44 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $30.18 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $29.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.72 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.88 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 955 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 915 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 588 | 143 |
| Metformin Hcl | Metformin Hcl | 376 | 105 |
| Omeprazole | Omeprazole | 376 | 86 |
| Simvastatin | Simvastatin | 329 | 62 |
| Losartan Potassium | Losartan Potassium | 320 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 69 |
| Gabapentin | Gabapentin | 273 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 55 |
| Famotidine | Famotidine | 226 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 50 |
| Lisinopril | Lisinopril | 201 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 195 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 45 |
| Alendronate Sodium | Alendronate Sodium | 161 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 41 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 154 | 27 |
| Furosemide | Furosemide | 145 | 28 |
| Potassium Chloride | Potassium Chloride | 143 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 64 |
| Meloxicam | Meloxicam | 133 | 32 |
| Azithromycin | Azithromycin | 124 | 102 |
| Trazodone Hcl | Trazodone Hcl | 124 | 36 |
| Carvedilol | Carvedilol | 121 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 26 |
| Montelukast Sodium | Montelukast Sodium | 111 | 30 |
| Levetiracetam | Levetiracetam | 109 | 12 |
| Prednisone | Prednisone | 105 | 81 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 25 |
| Lorazepam | Lorazepam | 95 | 40 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 94 | 11 |
| Finasteride | Finasteride | 92 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 25 |
| Hydrocortisone | Hydrocortisone | 88 | 52 |
| Alprazolam | Alprazolam | 85 | 28 |
| Naproxen | Naproxen | 83 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 14 |
| Allopurinol | Allopurinol | 77 | 21 |
| Atenolol | Atenolol | 77 | 16 |
| Eliquis | Apixaban | 77 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 72 | 15 |
| Metformin Hcl Er | Metformin Hcl | 71 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 18 |
| Ibuprofen | Ibuprofen | 68 | 36 |
| Linzess | Linaclotide | 68 | suppressed |
| Jardiance | Empagliflozin | 65 | 18 |
| Glimepiride | Glimepiride | 64 | 19 |
| Carbamazepine | Carbamazepine | 63 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 36 |
| Donepezil Hcl | Donepezil Hcl | 60 | 18 |
| Benazepril Hcl | Benazepril Hcl | 56 | 15 |
| Divalproex Sodium | Divalproex Sodium | 56 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Lovastatin | Lovastatin | 55 | 13 |
| Meclizine Hcl | Meclizine Hcl | 53 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 15 |
| Glipizide | Glipizide | 52 | 17 |
| Amoxicillin | Amoxicillin | 50 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 42 |
| Spironolactone | Spironolactone | 50 | suppressed |
| Mupirocin | Mupirocin | 49 | 29 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Primidone | Primidone | 42 | suppressed |
| Budesonide | Budesonide | 41 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Azelastine Hcl | Azelastine Hcl | 39 | 15 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Timolol Maleate | Timolol Maleate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 23 |
| Baclofen | Baclofen | 35 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 35 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Phenobarbital | Phenobarbital | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Enulose | Lactulose | 32 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | 11 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | 11 |
| Cephalexin | Cephalexin | 31 | 30 |
| Diazepam | Diazepam | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 11 |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 27 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 15 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Prolia | Denosumab | 24 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Lactulose | Lactulose | 23 | 12 |
| Sucralfate | Sucralfate | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Digoxin | Digoxin | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Vienva | Levonorgestrel/Ethin.Estradiol | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $567.05 · 22 records | ACADIA Pharmaceuticals Inc | AIRSUPRA, Cologuard Collection Kit, DAYBUE, FARXIGA, JARDIANCE, KISUNLA, LEQVIO, SMARTVEST, TRELEGY ELLIPTA, TZIELD, VALTOCO, VOQUEZNA, XIFAXAN, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error